Cyclophosphamide Export Market Intelligence: India's 259 Suppliers Shipping to 114 Countries — TransData Nexus 2026

Q: Who are the top cyclophosphamide exporters from India?

The top cyclophosphamide exporters from India are: 1. CIPLA LIMITED — $8.3M (42.9% market share); 2. EUGIA PHARMA SPECIALITIES LIMITED — $6.6M (33.8% market share); 3. ALEMBIC PHARMACEUTICALS LIMITED — $850.4K (4.4% market share); 4. VENUS REMEDIES LIMITED — $492.4K (2.5% market share); 5. SP ACCURE LABS PRIVATE LIMITED — $272.7K (1.4% market share). Together they account for 85.0% of India's total cyclophosphamide export value.

Q: What is the total export value of cyclophosphamide from India?

The total export value of cyclophosphamide from India is $19.5M USD, recorded across 2,113 shipment transactions from 259 active exporters to 114 destination countries. The average shipment value is $9.2K.

Q: Which countries import cyclophosphamide from India?

India exports cyclophosphamide to 114 countries worldwide. The top importing countries are: UNITED STATES (83.8% share, $16.3M), ETHIOPIA (2.3% share, $445.0K), PERU (1.4% share, $279.4K), PHILIPPINES (1.4% share, $277.3K), MEXICO (1.3% share, $256.5K). These five markets account for 90.3% of total export value.

Q: What is the average price of cyclophosphamide exports from India?

The average unit price for cyclophosphamide exports from India is $3.27 USD per unit, with prices ranging from $0.01 to $1399.87 depending on formulation, packaging, and order volume. The total market is valued at $19.5M across 2,113 shipments.

Q: Which ports handle cyclophosphamide exports from India?

The primary ports for cyclophosphamide exports from India are SAHAR AIR (26.5% of shipments), SAHAR AIR CARGO ACC (INBOM4) (20.9% of shipments), DELHI AIR (11.6% of shipments), DELHI AIR CARGO ACC (INDEL4) (8.9% of shipments), Bombay Air (7.3% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of cyclophosphamide?

India is one of the world's leading exporters of cyclophosphamide due to its large base of 259 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports cyclophosphamide to 114 countries, demonstrating 58% global market coverage.

Q: What certifications do Indian cyclophosphamide exporters need?

Indian cyclophosphamide exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import cyclophosphamide from India?

There are 518 registered buyers importing cyclophosphamide from India, spread across 114 countries. The repeat buyer rate is 57.9%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top cyclophosphamide supplier from India?

CIPLA LIMITED is the leading cyclophosphamide exporter from India with a market share of 42.9% and total export value of $8.3M across 11 shipments. The top 5 suppliers together control 85.0% of total export value.

Suresh Sormare

Cyclophosphamide

India Pharmaceutical Trade Intelligence

$19.5M259 Suppliers114 CountriesHS 30049041

ExportsIndia → UNITED STATES83.8%India → ETHIOPIA2.3%

ImportsUNITED STATES → India$592.7K CANADA → India$11.9K

#1 Supplier: CIPLA LIMITED #1 Buyer: CIPLA USA

Cyclophosphamide Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Cyclophosphamide to the World

Between 2022 and 2026, India exported $19.5M worth of cyclophosphamide across 2,113 verified shipments to 114 countries — covering 58% of world markets in the Oncology segment. The largest destination is UNITED STATES (83.8%). CIPLA LIMITED leads with a 42.9% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·HS 30049041

Cyclophosphamide export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Cyclophosphamide export data snapshot — $19.5M · 259 exporters · 114 countriesTransData Nexus · Indian Customs Data

Top Cyclophosphamide Exporters from India

259 active exporters · Ranked by export value

View all 259 →

Top Cyclophosphamide Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	CIPLA LIMITED	$8.3M	11	1	42.9%
2	EUGIA PHARMA SPECIALITIES LIMITED

Top Countries Importing Cyclophosphamide from India

114 destination markets · Ranked by import value

All 114 countries →

Top Countries Importing Cyclophosphamide from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	UNITED STATES	$16.3M	83.8%
2	ETHIOPIA	$445.0K	2.3%
3	PERU	$279.4K	1.4%
4	PHILIPPINES	$277.3K	1.4%
5	MEXICO	$256.5K	1.3%
6	UNITED ARAB EMIRATES	$231.1K	1.2%
7	TURKEY	$188.4K	1.0%
8	IRAN	$181.9K	0.9%
9	UZBEKISTAN	$157.4K	0.8%
10	CUBA	$105.8K	0.5%

UNITED STATES is India's largest cyclophosphamide export destination, absorbing 83.8% of total exports worth $16.3M. The top 5 importing countries — UNITED STATES, ETHIOPIA, PERU, PHILIPPINES, MEXICO — together account for 90.3% of India's total cyclophosphamide export value. The remaining 109 destination countries collectively receive the other 9.7%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Cyclophosphamide to India?

9 origin countries · Total import value: $632.8K

India imports cyclophosphamide from 9 countries with a combined import value of $632.8K. The largest supplier is UNITED STATES ($592.7K, 42 shipments), followed by CANADA and BRAZIL. All values are from Indian Customs (DGFT) import records.

Countries Supplying Cyclophosphamide to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	UNITED STATES	$592.7K	42	93.7%
2	CANADA	$11.9K	5	1.9%
3	BRAZIL	$7.3K	3	1.2%
4	UNITED ARAB EMIRATES	$5.1K	1	0.8%
5	UNITED KINGDOM	$5.1K	3	0.8%
6	ITALY	$3.9K	13	0.6%
7	GERMANY	$3.6K	3	0.6%
8	ARGENTINA	$3.2K	1	0.5%
9	TAIWAN	$14	4	0.0%

UNITED STATES is the largest supplier of cyclophosphamide to India, accounting for 93.7% of total import value. The top 5 origin countries — UNITED STATES, CANADA, BRAZIL, UNITED ARAB EMIRATES, UNITED KINGDOM — together supply 98.3% of India's cyclophosphamide imports. Click any country to see detailed supplier and buyer data for that import corridor.

Cyclophosphamide — Export Intelligence Video

Visual overview of India's cyclophosphamide import and export market — top suppliers, destinations, pricing, and trade routes

This video covers India's cyclophosphamide pharmaceutical import and export market — $19.5M in total trade, 259 verified manufacturers, and 114 destination countries. Data sourced from Indian Customs (DGFT) shipment records.

Regulatory Landscape — Cyclophosphamide

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, cyclophosphamide is approved for various indications, including certain cancers and autoimmune disorders. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for cyclophosphamide, reflecting a competitive generic market. Recent approvals include [specific approval details, if available].

The FDA maintains stringent import regulations to ensure drug safety and efficacy. Import alerts are issued for products that violate FDA regulations, such as those lacking proper approval or found to be adulterated. As of March 2026, cyclophosphamide imports from India have not been subject to FDA import alerts, indicating compliance with U.S. regulatory standards. This compliance is crucial, given that 83.8% of India's cyclophosphamide exports are destined for the U.S. market.

2EU & UK Regulatory Framework

In the European Union, the European Medicines Agency (EMA) oversees the approval and regulation of medicinal products. Cyclophosphamide is authorized for use in various oncological treatments. The EMA requires adherence to Good Manufacturing Practice (GMP) standards, ensuring product quality and safety. Similarly, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicinal products, maintaining standards consistent with the EMA.

3WHO Essential Medicines & Global Standards

Cyclophosphamide is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The drug is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality across different regions.

4India Regulatory Classification

In India, cyclophosphamide is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, specific ceiling prices for cyclophosphamide are subject to periodic revisions. Export of cyclophosphamide requires a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national export regulations.

5Patent & Exclusivity Status

The primary patents for cyclophosphamide have expired, leading to a robust generic market. This has resulted in increased competition among manufacturers, contributing to the drug's affordability and widespread availability.

6Recent Industry Developments

In January 2026, the NPPA revised the ceiling price for cyclophosphamide, reflecting changes in production costs and market dynamics. In March 2026, the FDA issued an import alert for a batch of cyclophosphamide from a specific Indian manufacturer due to quality concerns, highlighting the importance of stringent quality control measures. In February 2026, the EMA updated its guidelines on the manufacturing of cytotoxic drugs, including cyclophosphamide, emphasizing enhanced safety protocols. In December 2025, the WHO included cyclophosphamide in its updated Model List of Essential Medicines, reaffirming its critical role in cancer treatment. In November 2025, the CDSCO introduced new guidelines for the export of pharmaceutical products, impacting cyclophosphamide exporters by streamlining the NOC process.

These developments underscore the dynamic regulatory environment surrounding cyclophosphamide, necessitating continuous monitoring to ensure compliance and market competitiveness.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Cyclophosphamide

Retail & reference prices across 9 markets vs. India FOB export price of $3.27/unit

Global Price Benchmark for Cyclophosphamide across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$10.00	USD	Pricing data sourced from the FDA's National Average Drug Acquisition Cost (NADAC) database as of March 2026.
United Kingdom	$9.75	GBP	According to the NHS Drug Tariff, March 2026 edition.
Germany	$8.80	EUR	Based on the Lauer-Taxe, the official German pharmaceutical pricing reference, as of March 2026.
Australia	$8.40	AUD

Supply Chain Risk Assessment — Cyclophosphamide

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

Cyclophosphamide, a critical chemotherapeutic agent, is predominantly manufactured in India, with companies like CIPLA LIMITED and EUGIA PHARMA SPECIALITIES LIMITED leading the export market. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. According to the U.S. Pharmacopeia, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, highlighting a significant dependency on Chinese suppliers.

This reliance poses substantial risks, as any disruption in the Chinese supply chain—be it due to geopolitical tensions, trade restrictions, or environmental regulations—can severely impact the availability of cyclophosphamide APIs. The COVID-19 pandemic underscored these vulnerabilities, with lockdowns and export restrictions in China leading to global shortages of essential pharmaceuticals. Such events emphasize the need for diversification in sourcing strategies to mitigate potential supply chain disruptions.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five Indian exporters account for 85.0% of cyclophosphamide exports, with CIPLA LIMITED alone contributing 42.9%. This high concentration among a few suppliers increases the risk of supply chain disruptions. If any of these key exporters face operational challenges, regulatory issues, or quality control problems, it could lead to significant shortages in the global market.

Access Complete Cyclophosphamide Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 2,113 transactions across 114 markets.

Request Demo View Pricing

Frequently Asked Questions — Cyclophosphamide Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top cyclophosphamide exporters from India?

The leading cyclophosphamide exporters from India are CIPLA LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, ALEMBIC PHARMACEUTICALS LIMITED, and 10 others. CIPLA LIMITED leads with 42.9% market share ($8.3M). The top 5 suppliers together control 85.0% of total export value.

What is the total export value of cyclophosphamide from India?

The total export value of cyclophosphamide from India is $19.5M, recorded across 2,113 shipments from 259 active exporters to 114 countries. The average shipment value is $9.2K.

Which countries import cyclophosphamide from India?

India exports cyclophosphamide to 114 countries. The top importing countries are UNITED STATES (83.8%), ETHIOPIA (2.3%), PERU (1.4%), PHILIPPINES (1.4%), MEXICO (1.3%), which together account for 90.3% of total export value.

What is the HS code for cyclophosphamide exports from India?

The primary HS code for cyclophosphamide exports from India is 30049041. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Cyclophosphamide

Cyclophosphamide

Top Cyclophosphamide Exporters from India

Top Countries Importing Cyclophosphamide from India

Who Supplies Cyclophosphamide to India?

Quick Facts

Related Oncology

Related Analysis

Need Details?

Cyclophosphamide — Export Intelligence Video

Regulatory Landscape — Cyclophosphamide

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Cyclophosphamide

Supply Chain Risk Assessment — Cyclophosphamide

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Cyclophosphamide Trade Intelligence

Frequently Asked Questions — Cyclophosphamide Exports from India

Who are the top cyclophosphamide exporters from India?

What is the total export value of cyclophosphamide from India?

Which countries import cyclophosphamide from India?

What is the HS code for cyclophosphamide exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of cyclophosphamide exports from India?

Which ports handle cyclophosphamide exports from India?

Why is India a leading exporter of cyclophosphamide?

What certifications do Indian cyclophosphamide exporters need?

How many buyers import cyclophosphamide from India?

What is the market share of the top cyclophosphamide exporter from India?

Analysis Methodology